Single-particle cryo-electron microscopy (cryo-EM SPA) has recently emerged as an exceptionally well-suited technique for determining the structure of membrane proteins (MPs). Indeed, in the last years, it was observed a huge increase in the number of MPs solved by cryo-EM SPA at a resolution better than 3.0 Å in the Protein Data Bank (PDB). However, sample preparation remains a significant challenge in the field. Here, we evaluated in the MPs solved by cryo-EM SPA deposited in the PDB in the last two years at a resolution below 3.0 Å the most critical parameters for sample preparation: i) the surfactant used for protein extraction from the membrane, ii) the surfactant, amphiphiles, nanodiscs or other molecules present in the vitrification step, iii) the vitrification method employed, and iv) the type of grids used. The aim is not to provide a definitive answer on the optimal sample conditions for cryo-EM SPA of MPs, but rather assess the current trends in the MP structural biology community towards obtaining high-resolution cryo-EM structures.

Biomimetic delivery systems (BDSs), inspired by the intricate designs of biological systems, have emerged as a groundbreaking paradigm in nanomedicine, offering unparalleled advantages in therapeutic delivery. These systems, encompassing platforms such as liposomes, protein-based nanoparticles, extracellular vesicles, and polysaccharides, are lauded for their targeted delivery, minimized side effects, and enhanced therapeutic outcomes. However, the translation of BDSs from research settings to clinical applications is fraught with challenges, including reproducibility concerns, physiological stability, and rigorous efficacy and safety evaluations. Furthermore, the innovative nature of BDSs demands a reevaluation and evolution of existing regulatory and ethical frameworks. This review provides an overview of BDSs, delve into the multifaceted translational challenges and present emerging solutions, underscored by real-world case studies. Emphasizing the potential of BDSs to redefine healthcare, we advocate for sustained interdisciplinary collaboration and research. As our understanding of biological systems deepens, the future of BDSs in clinical translation appears promising, with a focus on personalized medicine and refined patient-specific delivery systems.

Magnetic Resonance Imaging (MRI) is a powerful, non-invasive and nondestructive tool, capable of providing three-dimensional (3D) images of living organisms. The use of magnetic contrast agents has allowed clinical researchers and analysts to enormously increase the sensitivity and specificity of MRI since these substances change the intrinsic properties of the tissues within a living body, increasing the information present in the images. The advances in nanotechnology and materials science as well as the research of new magnetic effects have been the driving forces that propel the use of magnetic nanostructures as promising alternatives to the commercial contrast agents used in MRI. This review discusses the principles associated with the use of contrast agents in MRI as well as the most recent reports focused on nanostructured contrast agents. The potential applications of gadolinium (Gd) and manganese Mn-based nanomaterials and iron oxide nanoparticles in this imaging technique are discussed as well, from their magnetic behavior to the mainly used materials and nanoarchitectures. Then, it is also addressed the recent efforts made to develop new types of contrast agents based on synthetic antiferromagnetic and high-aspect ratio nanostructures. Furthermore, the application of these materials in theragnosis, either as contrast agents and controlled drug release, contrast agents and thermal therapy or contrast agents and radiosensitizers, is also presented.